Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

portion of debt 5,275 4,976

Warrants liability 2,492 -

Total current liabilities 11,318 11,755

Debt, less current portion 6,342 5,754

Deferred rent 15,415 10,145

Commitments and contingencies

Stockholders' equity:

Preferred stock, $0.001 par value 5,000,000

shares authorized; no shares issued

and outstanding at December 31, 2007 and 2006,

respectively - -

Common stock, $0.001 par value 75,000,000

shares authorized; 41,168,432 and 29,060,081

issued and outstanding at December 31, 2007

and 2006, respectively 41 29

Additional paid-in capital 233,807 200,497

Accumulated other comprehensive income 7 3

Deficit accumulated during the development

stage (198,975) (155,894)

Total stockholders' equity 34,880 44,635

Total liabilities and stockholders' equity $67,955 $72,289

FAVRILLE, INC.

(a development stage company)

STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

Three months ended

Years ended December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited) (unaudited)

Operating expenses:

Research &

development $34,864 $31,050 $7,764 $7,680

<
'/>"/>
SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Niagara Thermal Products is proud to announce that ... ("B3") as the critical thermal component supplier in support ... Corps of Engineers.  B3 has developed the only comprehensive ... destroys VOCs and other chemical pollutants, allergens and organic ...
(Date:1/15/2014)... Calif. (PRWEB) January 15, 2014 Cynvenio, ... and management through the genomic analysis of tumor cells ... Therapy Finder™, a web-based cancer decision support application powered ... option with Cynvenio’s ClearID™ genomic test, Therapy Finder will ...
(Date:1/15/2014)... ­ RedBrick Health , a fast-growing leader in ... that EmblemHealth , the New York ... providing the RedBrick Compass health assessment, combined with the ... its members. EmblemHealth is among the first health plans ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... ... firm today announced that LI-COR is moving its B2B sales into the Cloud with the ... ... Consulting , a leading technology services firm today announced that LI-COR is moving its B2B ...
... The University of Georgia Research Foundation, Inc. (UGARF) and ... non-exclusive license for a portfolio of glow-in-the-dark pigments that ... of the visible spectrum for nearly a day. ... Phosphorescence is a process in which energy ...
... , BETHESDA, Md., Aug. 17 Spherix Incorporated (Nasdaq: ... of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, ... , Recent and Upcoming Company Highlights , ... , Clinical trials on Naturlose ...
Cached Biology Technology:Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud" 2Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud" 3UGA, UPR grant license for long-persistence glow materials, in any color 2UGA, UPR grant license for long-persistence glow materials, in any color 3UGA, UPR grant license for long-persistence glow materials, in any color 4Spherix Reports Second Quarter 2009 Earnings 2Spherix Reports Second Quarter 2009 Earnings 3Spherix Reports Second Quarter 2009 Earnings 4Spherix Reports Second Quarter 2009 Earnings 5Spherix Reports Second Quarter 2009 Earnings 6Spherix Reports Second Quarter 2009 Earnings 7Spherix Reports Second Quarter 2009 Earnings 8
(Date:4/24/2014)... April 24, 2014D-ribose is a commercially important sugar ... as a starting compound for synthesizing riboflavin and ... coli to increase the bacteria,s ability to ... more efficient industrial-scale production of this valuable chemical, ... Biotechnology , a peer-reviewed journal from Mary Ann ...
(Date:4/24/2014)... Society of America (ESA) is very pleased to announce ... of Insect Science from the University of Wisconsin. ... is an international, open-access, peer-reviewed journal that publishes ... and other arthropods -- from the molecular to the ... impacts. It is freely available to individuals and institutions, ...
(Date:4/24/2014)... and the University of North Carolina at Chapel Hill ... identify arterial plaque that is at high risk of ... At issue is the plaque that builds up in ... deemed "vulnerable," meaning that they are more likely to ... or stroke. , "Existing state-of-the-art technologies are capable of ...
Breaking Biology News(10 mins):ESA to publish the Journal of Insect Science 2New ultrasound device may add in detecting risk for heart attack, stroke 2
... in how organisms grow and flourish, but studying their ... difficult. Now, a team of chemists and neurobiologists led ... Erin M. Schuman at the California Institute of Technology ... protein synthesis in specific locations. , The new method, ...
... at the University of Chicago show how the bacteria that ... how, by slightly altering one of the microbe's tools, the ... vaccine. , Both papers -- one published online July 28 ... Infection and Immunity -- focus on aspects of the type-III ...
... greatly benefit crop plants, scientists have deciphered the genome ... from diseases. , The research provides clues to better ... safeguards roots and seeds from infection by harmful microbes ... published in Nature Biotechnology and was scheduled to be ...
Cached Biology News:Protein synthesis can be controlled by light, opening way for new scientific, medical applications 2Protein synthesis can be controlled by light, opening way for new scientific, medical applications 3Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 2Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 3Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 4Genome study of beneficial microbe may help boost plant health 2
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
...
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
Biology Products: